Individualizing Surveillance Mammography for Older Breast Cancer Survivors

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-16

Study Completion Date

2021-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research is being conducted to develop consensus on surveillance mammography and follow-up for breast cancer survivors who are age ≥75.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

NCT07123649

Breast Cancer

NOT_YET_RECRUITING PHASE2

Surveillance Imaging Modalities for Breast Cancer Assessment

NCT02212834

Breast Cancer

COMPLETED

LCCC1931:Post-treatment Intervention in Women With Breast Cancer (70y/o+)

NCT04292847

Breast Cancer

COMPLETED

Automated Tele Counseling for Screening Mammography

NCT00247013

Breast Cancer

COMPLETED PHASE1

Dynamic Infrared Thermography in Breast Cancer Diagnostics

NCT02829021

Breast Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will develop a communication tool that summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors age ≥75. Developing expert-panel recommendations, examining clinician and patient attitudes towards these recommendations, and testing a strategy for communication of expert recommendations on mammography cessation through direct engagement of specialists, primary care clinicians (PCs), and patients.

This is a multi-step study, the investigators will build on prior steps to develop consensus on surveillance mammography and follow-ups for breast cancer survivors who are age \>= 75.

This study includes a physician focus group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Surveillance Mammography Communication Tool

* Conduct 30 telephone-based patient interviews
* 4-6 focus groups with oncologists and primary care providers (PCs) to learn their perceptions and thoughts about when to stop surveillance mammography
* Perform cognitive testing of the communication tool

Group Type EXPERIMENTAL

Communication Tool

Intervention Type OTHER

Summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Communication Tool

Summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female gender, given that screening guidelines do not exist for men
* Receiving part or all of their care at DFCI
* Ages 75-79 (approximately 15 patients)
* Age ≥80 (approximately 15 patients)
* History of stage 0-II breast cancer

-≥1 Charlson comorbidity present72, defined as one of the following:
* Diabetes
* Liver disease
* History of or other active malignancy other than non-melanoma skin cancers
* HIV or AIDS
* Chronic kidney disease
* History of myocardial infarction and/or congestive heart failure
* Chronic lung disease (emphysema/chronic bronchitis/chronic obstructive pulmonary disease \[COPD\], interstitial lung disease)
* Peripheral vascular disease
* Cerebrovascular disease (history of TIA or stroke)
* Dementia
* Hemiplegia/paralysis
* Connective tissue disorder
* Underwent breast conserving surgery for treatment of this cancer
* Completed all active breast cancer therapy \>3 months prior to enrollment (i.e. any chemotherapy, trastuzumab, radiation). Ongoing hormonal therapy or enrollment in survivorship clinical trials (aspirin, exercise, etc) is allowed.
* English-speaking and reading (for this initial work)
* Aim 1.1. Cognitive testing of the communication tool. The criteria for this are intentionally more flexible than in other aims, as we are simply working to initially test the tool and its readability and understandability. Patients will be eligible to cognitively test the tool if they meet the following criteria:
* Female gender
* Previous diagnosis of breast cancer
* Age ≥75
* Receive some/all care at Dana-Farber Cancer Institute
* English speaking-reading
* Aim 1.2. Pilot testing the communication tool in clinic.
* Previous diagnosis of stage 0-II breast cancer
* Receive some/all care at Dana-Farber Cancer Institute (main campus or St. Elizabeth's site)
* Completed any active breast cancer therapy \> 3 months prior to enrollment (i.e. any chemotherapy, trastuzumab, radiation). Ongoing hormonal therapy or enrollment in survivorship clinical trials (aspirin, exercise, etc) is allowed.
* Age ≥75
* Had breast-conserving surgery to treat this cancer

-≥1 the following comorbid conditions72 present, defined as the following:
* Diabetes
* Liver disease
* History of or other active malignancy other than non-melanoma skin cancers
* HIV or AIDS
* Chronic kidney disease
* History of myocardial infarction and/or congestive heart failure
* Chronic lung disease (COPD, interstitial lung disease)
* Peripheral vascular disease
* Cerebrovascular disease (history of TIA or stroke)
* Dementia
* Hemiplegia/paralysis
* Connective tissue disorder
* Provider does not opt out of the patient's enrollment via email notification
* Blessed Orientation Memory Concentration (COMC) score is \<10 and capacity is met73 (see Appendix A for BOMC scale)
* Providers of participating patients will be sent a one-time survey but there are no other eligibility for providers to participate in this other than their patient participated
* English speaking and reading